EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SRC Activation Drives Acquired Pemetrexed Resistance in Non‐Small Cell Lung Cancer and Is Targetable by Dasatinib

Jeongmin Seo iD, Kui-Jin Kim, Se Hyun Kim iD, Ji Hea Sung, Sung-Hyun Hwang iD, Woochan Park iD, Minsu Kang iD, Eun Hee Jung, Sang-A Kim iD, Koung Jin Suh, Ji Yun Lee iD, Ji-Won Kim iD und 8 weitere

Thoracic Cancer · 2026-10 · 17 (20)

DOI: 10.1111/1759-7714.70406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 23.10.2026. Verfasst von Jeongmin Seo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Kor…. Hauptthemen laut MEDLINE: Dasatinib, Carcinoma, Non-Small-Cell Lung, Pemetrexed, Drug Resistance, Neoplasm. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Seoul National University Bundang Hospital Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Pemetrexed, a standard antifolate chemotherapy for non‐squamous non‐small cell lung cancer (NSCLC), is often limited by acquired resistance. We investigated whether SRC kinase mediates pemetrexed resistance and whether SRC inhibition can suppress survival signaling in pemetrexed‐resistant NSCLC cells.

Methods

Pemetrexed‐resistant cell lines (PC9 R, NCI‐H460 R, and NCI‐H3122 R) were generated through chronic pemetrexed exposure. Protein phosphorylation profiling and Western blotting identified key signaling alterations. SRC was abrogated using transient and doxycycline‐inducible CRISPR/Cas9 systems, and reciprocal siRNA knockdown of SRC and thymidylate synthase (TS) was performed. Three SRC inhibitors—dasatinib, bosutinib, and saracatinib—were assessed using cell viability, colony formation, apoptosis, and cell cycle assays.

Results

All pemetrexed‐resistant cell lines demonstrated elevated phosphorylated SRC (p‐SRC Y416) and enhanced downstream signaling. SRC knockout reduced p‐SRC Y416, p‐STAT3, and p‐FAK, while increasing markers of DNA damage (γ‐H2AX) and apoptosis (cleaved caspase‐3), impairing cell viability and clonogenicity. SRC knockdown reduced TS expression in two resistant models, whereas TS knockdown did not suppress p‐SRC Y416. Among SRC inhibitors, dasatinib showed the most potent, dose‐dependent suppression of SRC signaling. Dasatinib also induced G0/G1 arrest, DNA damage, and apoptosis, thereby reducing colony formation.

Conclusion

SRC activation is a critical mechanism of acquired pemetrexed resistance in NSCLC and may contribute to resistance through TS‐associated survival signaling. SRC inhibition, particularly with dasatinib, disrupts pro‐survival pathways and promotes DNA damage‐mediated cell death in pemetrexed‐resistant cells. These findings support further investigation of SRC inhibitors, alone or with pemetrexed, as a biomarker‐guided therapeutic strategy for SRC‐activated pemetrexed‐resistant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibCarcinoma, Non-Small-Cell LungPemetrexedDrug Resistance, NeoplasmLung Neoplasmssrc-Family KinasesHumansCell Line, TumorApoptosisProtein Kinase InhibitorsSignal TransductionCell ProliferationTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

SRCacquired resistancedasatiniblung cancerpemetrexed

Substanzen

DasatinibPemetrexedsrc-Family KinasesProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  • Biomedical Research Institute, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.

ORCID-Profile: Jeongmin Seo, Se Hyun Kim, Sung-Hyun Hwang, Woochan Park, Minsu Kang, Sang-A Kim, Ji Yun Lee, Ji-Won Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee

Förderung

  • Seoul National University Bundang Hospital Research Fund

Zitieren

APA

Seo, J., Kim, K. J., Kim, S. H., Sung, J. H., Hwang, S. H., Park, W., Kang, M., Jung, E. H., Kim, S. A., Suh, K. J., Lee, J. Y., Kim, J. W., Lee, J. O., Kim, J. W., Kim, Y. J., Lee, K. W., Kim, J. H., Bang, S. M., Kwon, J. H., & Lee, J. S. (2026). SRC Activation Drives Acquired Pemetrexed Resistance in Non‐Small Cell Lung Cancer and Is Targetable by Dasatinib. Thoracic Cancer, 17(20). https://doi.org/10.1111/1759-7714.70406

Vancouver

Seo J, Kim KJ, Kim SH, Sung JH, Hwang SH, Park W, et al. SRC Activation Drives Acquired Pemetrexed Resistance in Non‐Small Cell Lung Cancer and Is Targetable by Dasatinib. Thoracic Cancer. 2026;17(20). doi:10.1111/1759-7714.70406

BibTeX
@article{Seo2026,
  author = {Seo, Jeongmin and Kim, Kui-Jin and Kim, Se Hyun and Sung, Ji Hea and Hwang, Sung-Hyun and Park, Woochan and Kang, Minsu and Jung, Eun Hee and Kim, Sang-A and Suh, Koung Jin and Lee, Ji Yun and Kim, Ji-Won and Lee, Jeong-Ok and Kim, Jin Won and Kim, Yu Jung and Lee, Keun-Wook and Kim, Jee Hyun and Bang, Soo-Mi and Kwon, Ji-Hyun and Lee, Jong Seok},
  title = {SRC Activation Drives Acquired Pemetrexed Resistance in Non‐Small Cell Lung Cancer and Is Targetable by Dasatinib},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {20},
  doi = {10.1111/1759-7714.70406}
}
Kostenlos starten →